AFP and neoplasm: Eligibility is determined by a multidisciplinary tumour board, with decisions guided by treatment response, recurrence-free intervals, and both the reduction and sustained stability of AFP levels—closely aligning with the downstaging principles outlined in the UNOS-DS criteria [45].